GlobalData on MSN8d
EC approves CSL’s Andembry to stop hereditary angioedema attacksCSL has received approval from the European Commission (EC) for Andembry (garadacimab) to prevent recurrent attacks of ...
GlobalData on MSN1d
Japan’s MHLW approves CSL Behring’s Andembry to stop HAE attacksCSL Behring KK has gained approval from Japan's Ministry of Health, Labour and Welfare (MHLW) to manufacture and market ...
Astria advances innovative therapies for hereditary angioedema and atopic dermatitis. Strong cash position supports pivotal ...
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that six abstracts have been accepted for presentation at the American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy ...
Intellia has reported results from a phase 2 trial of its gene-editing drug for hereditary angioedema ... but frequently do not eliminate all, angioedema attacks and require lifelong administration.
Dr Ruchi Gupta provides AAAAI/WAO 2025 highlights, including anticipated presentations, quick takeaways, and insights into ...
Global biotechnology leader CSL has announced that the European Commission (EC) has approved ANDEMBRY (garadacimab), the ...
(berotralstat) is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older. Limitations of use ...
has approved ANDEMBRY® (garadacimab), the first and only once-monthly treatment targeting factor XIIa to prevent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 ...
ANDEMBRY®, the first and only once-monthly treatment targeting factor XIIa to prevent attacks in HAE patients ... in the management of hereditary angioedema, offering people living with this ...
The European Commission (EC) has approved CSL’s Andembry (garadacimab) to prevent attacks of hereditary angioedema (HAE) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback